Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 10/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.55 |
| ▸ | ITK | Q08881 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431857 | 0.84 | TBK1 (0.75) | TBK1PDPK1 | |
| SCHEMBL13653693 | 0.84 | TBK1 (0.51) | TBK1PDPK1EGFRSYKCNR2 | |
| SCHEMBL13460187 | 0.82 | TBK1 (0.51) | TBK1PDPK1EGFRSYKCNR2 | |
| SCHEMBL13432004 | 0.80 | TBK1 (0.51) | TBK1PDPK1EGFRSYKCNR2 | |
| Hydrochloric Acid SCHEMBL3384212 | 0.79 | TBK1 (0.50) | TBK1PDPK1EGFRSYKCNR2 | |
| SCHEMBL13432016 | 0.77 | STK17B (0.55) | CNR2 | |
| SCHEMBL3387851 | 0.77 | TBK1 (0.59) | TBK1PDPK1ITKEGFRSYK | |
| SCHEMBL3388237 | 0.75 | TBK1 (0.77) | TBK1PDPK1 | |
| SCHEMBL13431757 | 0.74 | TBK1 (0.79) | TBK1PDPK1 | |
| Trifluoroacetic Acid SCHEMBL3387029 | 0.74 | TBK1 (0.72) | TBK1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TBK1 2898/4885PDPK1 2468/4885ITK 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.